North B B, Vorhauer B W
Int J Fertil. 1985;30(1):81-4.
Use of the TODAY contraceptive sponge in the U.S. has been monitored in three ways since it became an OTC product in June, 1983: The Phase III clinical trials in the U.S. were extended for a second year (Life Table method efficacy rate for a second year of use = 96.6%; N = 103). The manufacturer has solicited comments and complaints from family planning professionals and from women who purchased sponges over-the-counter. One complaint has been received for every 33,000 sponges distributed, primarily related to removal difficulty, infection and allergy to spermicide. By December of 1984, there were an estimated 1.25 million sponge users in the U.S. Voluntary, spontaneous reporting to regulatory or health agencies has tracked case reports of toxic shock syndrome (TSS) in sponge users. To date 13 cases have been reported with over 25 million sponges sold. The risk of TSS in sponge users is thus very small and may not represent an increased risk over baseline.
自1983年6月成为非处方药以来,美国对今日避孕海绵的使用情况通过三种方式进行了监测:美国的III期临床试验延长了一年(第二年使用的生命表法有效率 = 96.6%;N = 103)。制造商已向计划生育专业人员以及通过非处方购买海绵的女性征求意见和投诉。每分发33,000个海绵收到一份投诉,主要涉及取出困难、感染和对杀精剂过敏。到1984年12月,美国估计有125万海绵使用者。向监管机构或卫生机构进行的自愿自发报告追踪了海绵使用者中毒性休克综合征(TSS)的病例报告。迄今为止,已售出超过2500万个海绵,报告了13例病例。因此,海绵使用者发生TSS的风险非常小,可能并不表示相对于基线风险有所增加。